64 related articles for article (PubMed ID: 21247791)
1. Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.
Ziebart T; Koch F; Klein MO; Guth J; Adler J; Pabst A; Al-Nawas B; Walter C
Oral Oncol; 2011 Mar; 47(3):195-201. PubMed ID: 21247791
[TBL] [Abstract][Full Text] [Related]
2. Geranylgeraniol prevents zoledronic acid-mediated reduction of viable mesenchymal stem cells via induction of Rho-dependent YAP activation.
Singhatanadgit W; Hankamolsiri W; Janvikul W
R Soc Open Sci; 2021 Jun; 8(6):202066. PubMed ID: 34113452
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws.
Koneski F; Popovic-Monevska D; Gjorgoski I; Krajoska J; Popovska M; Muratovska I; Velickovski B; Petrushevska G; Popovski V
J Craniomaxillofac Surg; 2018 Feb; 46(2):230-236. PubMed ID: 29233701
[TBL] [Abstract][Full Text] [Related]
4. Geranylgeraniol (GGOH), incorporated into a bone cement pellet promotes osteoclast function and healing in a model of medication-related osteonecrosis of the jaw.
Feldman G; Young D; Freeman T; Israel L; Taub D; Diecidue R
J Oral Biol Craniofac Res; 2024; 14(2):126-132. PubMed ID: 38327595
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies.
Jiang A; Zhang Z; Qiu X; Guo Q
Arch Toxicol; 2024 Mar; 98(3):689-708. PubMed ID: 38155341
[TBL] [Abstract][Full Text] [Related]
6. Geranylgeraniol Application in Human Osteoblasts and Osteoclasts for Reversal of the Effect of Bisphosphonates.
Jung J; Park JS; Chun J; Al-Nawas B; Ziebart T; Kwon YD
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374134
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.
Guirguis RH; Tan LP; Hicks RM; Hasan A; Duong TD; Hu X; Hng JYS; Hadi MH; Owuama HC; Matthyssen T; McCullough M; Canfora F; Paolini R; Celentano A
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371553
[TBL] [Abstract][Full Text] [Related]
8. The Biomedical Importance of the Missing Pathway for Farnesol and Geranylgeraniol Salvage.
Verdaguer IB; Crispim M; Hernández A; Katzin AM
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557825
[TBL] [Abstract][Full Text] [Related]
9.
Rattanawonsakul K; Bullock G; Bolt R; Claeyssens F; Atkins S; Hearnden V
Front Oral Health; 2022; 3():892615. PubMed ID: 35795156
[TBL] [Abstract][Full Text] [Related]
10. The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw.
Chin KY; Ekeuku SO; Trias A
Front Pharmacol; 2022; 13():878556. PubMed ID: 35600875
[TBL] [Abstract][Full Text] [Related]
11. Co-Treatment of Purified Annatto Oil (
Pereira ACM; de Oliveira Carvalho H; Gonçalves DES; Picanço KRT; de Lima Teixeira Dos Santos AVT; da Silva HR; Braga FS; Bezerra RM; de Sousa Nunes A; Nazima MTST; Cerqueira JG; Taglialegna T; Teixeira JM; Carvalho JCT
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443306
[TBL] [Abstract][Full Text] [Related]
12. Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Otto M; Lux C; Schlittenbauer T; Halling F; Ziebart T
Oral Maxillofac Surg; 2022 Jun; 26(2):321-332. PubMed ID: 34392434
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of dietary geranylgeraniol on glucose homeostasis and bone microstructure in obese mice is associated with suppression of proinflammation and modification of gut microbiome.
Chung E; Elmassry MM; Cao JJ; Kaur G; Dufour JM; Hamood AN; Shen CL
Nutr Res; 2021 Sep; 93():27-37. PubMed ID: 34352722
[TBL] [Abstract][Full Text] [Related]
14. Mechanism, prevention, and treatment for medication-related osteonecrosis of the jaws.
Pan J; Liu JY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Jun; 39(3):245-254. PubMed ID: 34041871
[TBL] [Abstract][Full Text] [Related]
15. Timing of geranylgeraniol addition increases osteoblast activities under alendronate condition.
Mungpayabarn H; Patntirapong S
J Oral Biol Craniofac Res; 2021; 11(3):396-401. PubMed ID: 34026481
[TBL] [Abstract][Full Text] [Related]
16. Standardized
Wiziack Zago PM; Oliveira Sousa IM; Servat-Medina L; Jorge MP; Lima Neto LG; Hass V; Li X; Tasca Gois Ruiz AL; Saxena D; Foglio MA
Clin Cosmet Investig Dent; 2020; 12():327-333. PubMed ID: 32848479
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Reverses the Inhibitory Effects of the Bisphosphonate, Zoledronic Acid, on Human Oral Keratinocytes and Human Vascular Endothelial Cells In Vitro via the Epidermal Growth Factor Receptor (EGFR)/Akt/Phosphoinositide 3-Kinase (PI3K) Signaling Pathway.
Wang Q; Liu J; Guo T; Liu D; Pan J
Med Sci Monit; 2019 Jan; 25():700-710. PubMed ID: 30675875
[TBL] [Abstract][Full Text] [Related]
18. Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).
Kwon YD; Kim DY
Dent J (Basel); 2016 Nov; 4(4):. PubMed ID: 29563483
[TBL] [Abstract][Full Text] [Related]
19. Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw.
Rahimi-Nedjat RK; Sagheb K; Pabst A; Olk L; Walter C
Dent J (Basel); 2016 May; 4(2):. PubMed ID: 29563459
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.
Pabst AM; Krüger M; Blatt S; Ziebart T; Rahimi-Nedjat R; Goetze E; Walter C
Dent J (Basel); 2016 Dec; 5(1):. PubMed ID: 29563407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
